Cardiovascular benefits of air purifier in patients with stable coronary artery disease: A randomized single-blind crossover study

Zhe Liu; Qin Wang; Na Li; Chunyu Xu; Yunpu Li; Jun Zhou; Liu Liu; Haijing Zhang; Feng Han; Dongqun Xu

doi:10.3389/fpubh.2022.1082327

journal article Open Access Jan 09, 2023

Cardiovascular benefits of air purifier in patients with stable coronary artery disease: A randomized single-blind crossover study

Zhe Liu

Qin Wang

Na Li

Chunyu Xu Yunpu Li Jun Zhou

Liu Liu

Haijing Zhang

Feng Han

Dongqun Xu

Frontiers in Public Health Vol. 10 · Frontiers Media SA

View at Publisher Save 10.3389/fpubh.2022.1082327

Abstract

BackgroundExposure to PM2.5 will accelerate the progression of cardiovascular diseases. Air purifier can reduce the PM2.5 exposure and theoretically alleviate the influence of PM2.5 on patients with stable coronary artery disease (SCAD). However, few studies of the protective effect showed significant results because the interferent effects of routine medication had not been taken into account. In order to explore the actual effect on patients with SCAD, we conducted a randomized single-blind crossover air purifier intervention trial.MethodLevels of PM2.5 exposure during intervention and cardiovascular indicators (inflammation, coagulation, plaque stability, and blood lipids) after intervention were detected, meanwhile the information of drug use was obtained by questionnaire. The kinds of drug used by more than 20% of the subjects were sorted out. And the influence of these drugs on cardiovascular indicators was summarized through literature review. Based on that, the drug use was included as a variable in linear mixed effects models that used to analyze the associations between PM2.5 exposure reduction by air purifier and cardiovascular indicators.ResultsThe result revealed that the interpretation contribution rate of drug use was more than that of PM2.5 exposure. The level of C-reactive protein significantly decreased by 20.93% (95%CI: 6.56%, 33.10%), 23.44% (95%CI: 2.77%, 39.39%) and 24.11% (95%CI: 4.21%, 39.69%) on lag1, lag01 and lag02 respectively, while the level of high-density lipoprotein cholesterol significantly increased by 5.10% (95%CI: 0.69%, 9.05%), 3.71% (95%CI: 0.92%, 6.60%) and 6.48% (95%CI: 2.58%, 10.24%) respectively on lag0, lag1 and lag01 associated with an interquartile range decrease of 22.51 μg/m3 in PM2.5 exposure.ConclusionThe study shows positive effects of air purifier on SCAD, and also provides methodological reference for future related research.

Topics

No keywords indexed for this article. Browse by subject →

References

81

[1]

Particulate Matter Air Pollution and Cardiovascular Disease

Robert D. Brook, Sanjay Rajagopalan, C. Arden Pope et al.

Circulation 2010 10.1161/cir.0b013e3181dbece1

[2]

Karottki "An indoor air filtration study in homes of elderly: cardiovascular and respiratory effects of exposure to particulate matter" Environ Health. (2013) 10.1186/1476-069x-12-116

[3]

Chu "Effects of high-efficiency particulate air purifiers on indoor fine particulate matter and its constituents in a district of Beijing during winter" J Peking Univ. (2018) 10.3969/j.issn.1671-167x.2018.03.015

[4]

Brauner "Indoor particles affect vascular function in the aged: an air filtration-based intervention study" Am J Respir Crit Care Med. (2008) 10.1164/rccm.200704-632oc

[5]

Chen "Cardiopulmonary benefits of reducing indoor particles of outdoor origin: a randomized, double-blind crossover trial of air purifiers" J Am Coll Cardiol. (2015) 10.1016/j.jacc.2015.03.553

[6]

Fine Particulate Air Pollution and the Expression of microRNAs and Circulating Cytokines Relevant to Inflammation, Coagulation, and Vasoconstriction

Renjie Chen, Huichu Li, Jing Cai et al.

Environmental Health Perspectives 2018 10.1289/ehp1447

[7]

Kajbafzadeh "The impacts of traffic-related and woodsmoke particulate matter on measures of cardiovascular health: a HEPA filter intervention study" Occup Environ Med. (2015) 10.1136/oemed-2014-102696

[8]

Allen "An air filter intervention study of endothelial function among healthy adults in a woodsmoke-impacted community" Am J Respir Crit Care Med. (2011) 10.1164/rccm.201010-1572oc

[9]

Chuang "Long-term indoor air conditioner filtration and cardiovascular health: a randomized crossover intervention study" Environ Int. (2017) 10.1016/j.envint.2017.06.008

[10]

Lin "Reducing indoor air pollution by air conditioning is associated with improvements in cardiovascular health among the general population" Sci Total Environ (2013) 10.1016/j.scitotenv.2013.05.093

[11]

Effects of air purification of indoor PM 2.5 on the cardiorespiratory biomarkers in young healthy adults

Yuxin Wang, Yan Zhao, Lijun Xue et al.

Indoor Air 2021 10.1111/ina.12815

[12]

Shao "Cardiorespiratory responses of air filtration: a randomized crossover intervention trial in seniors living in Beijing: Beijing Indoor Air Purifier StudY, BIAPSY" Sci Total Environ (2017) 10.1016/j.scitotenv.2017.06.095

[13]

Xu "Extreme levels of air pollution associated with changes in biomarkers of atherosclerotic plaque vulnerability and thrombogenicity in healthy adults" Circ Res. (2019) 10.1161/circresaha.118.313948

[14]

Liu "Adverse effects of air pollutant exposure on blood lipid levels in adults: a systematic review and meta-analysis" Cardiol Plus. (2020) 10.4103/cp.cp_18_20

[15]

2013 ESC guidelines on the management of stable coronary artery disease

European Heart Journal 2013 10.1093/eurheartj/eht296

[16]

Hu (2010)

[17]

"Guidelines for Rational Drug Use of Coronary Artery Disease (2nd Edition)" Chin J Front Med Sci (2018) 10.12037/yxqy.2018.06-01

[18]

Vukovic "Steroids and statins: an old and a new anti-inflammatory strategy compared" Perfusion. (2010) 10.1177/0267659110385607

[19]

Ascer "Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients" Atherosclerosis. (2004) 10.1016/j.atherosclerosis.2004.07.003

[20]

Gómez-García "Rosuvastatin and metformin decrease inflammation and oxidative stress in patients with hypertension and dyslipidemia" Rev Esp Cardiol. (2007) 10.1157/13113929

[21]

Kinlav "Effect of atorvastatin on C-reactive protein in patients with acute coronary syndromes: a substudy of the MIRACL trial" J Am Coll Cardiol. (2002) 10.1016/s0735-1097(02)81367-5

[22]

Riesen "Short-term effects of atorvastatin on C-reactive protein" Eur Heart J. (2002) 10.1053/euhj.2001.2967

[23]

Seljeflot "Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease" Atherosclerosis. (2002) 10.1016/s0021-9150(01)00696-7

[24]

Barale "Simvastatin effects on inflammation and platelet activation markers in hypercholesterolemia" Biomed Res Int. (2018) 10.1155/2018/6508709

[25]

Chu "Effects of atorvastatin and atorvastatin withdrawal on soluble CD40L and adipocytokines in patients with hypercholesterolaemia" Acta Cardiol. (2006) 10.2143/ac.61.3.2014826

[26]

Li "Effects of simvastatin on exercise-induced myocardial ischemia and plasma endothelin-1 concentrations in patients with stable angina" Clin Chim Acta. (2005) 10.1016/j.cccn.2004.10.012

[27]

Glorioso "Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia" Hypertension. (1999) 10.1161/01.hyp.34.6.1281

[28]

Atalar "Effects of short-term atorvastatin treatment on global fibrinolytic capacity, and sL-selectin and sFas levels in hyperlipidemic patients with coronary artery disease" Int J Cardiol. (2002) 10.1016/s0167-5273(02)00148-1

[29]

Cortellaro "Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study)" Thromb Haemost. (2000) 10.1055/s-0037-1613861

[30]

Qu "Effect of atorvastatin versus rosuvastatin on levels of serum lipids, inflammatory markers and adiponectin in patients with hypercholesterolemia" Pharm Res. (2009) 10.1007/s11095-008-9798-6

[31]

Koh "Non-lipid effects of statin on hypercholesterolemic patients established to have coronary artery disease who remained hypercholesterolemic while eating a step-II diet" Coron Artery Dis. (2001) 10.1097/00019501-200106000-00006

[32]

Koh "Comparative effects of diet and statin on NO bioactivity and matrix metalloproteinases in hypercholesterolemic patients with coronary artery disease" Arterioscler Thromb Vasc Biol. (2002) 10.1161/01.atv.0000030997.02059.bb

[33]

Tousoulis "Comparative effects of rosuvastatin and allopurinol on circulating levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with chronic heart failure" Int J Cardiol. (2010) 10.1016/j.ijcard.2009.05.051

[34]

Fujiwara "Decreased plasma and cardiac matrix metalloproteinase activities in patients with coronary artery disease and treated with pravastatin" Eur J Pharmacol. (2008) 10.1016/j.ejphar.2008.07.039

[35]

Koh "Comparative effects of statin and fibrate on nitric oxide bioactivity and matrix metalloproteinase in hyperlipidemia" Int J Cardiol. (2004) 10.1016/j.ijcard.2003.09.007

[36]

Karalis "Comparison of efficacy and safety of atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease" Am J Cardiol. (2002) 10.1016/s0002-9149(01)02337-2

[37]

Li "Therapeutic effects of metoprolol on ventricular remodeling and proinflammatory cytokines in patients with chronic heart failure" Chin Heart J. (2005) 10.3969/j.issn.1009-7236.2005.06.005

[38]

Ohtsuka "Effect of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy" J Am Coll Cardiol. (2001) 10.1016/s0735-1097(00)01121-9

[39]

Doo "Effect of beta blockers on expression of interleukin-6 and C-reactive protein in patients with unstable angina pectoris" Am J Cardiol. (2001) 10.1016/s0002-9149(01)01693-9

[40]

Rizos "The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study" J Cardiovasc Pharmacol Ther. (2003) 10.1177/107424840300800206

[41]

Seljeflot "Effects of doxazosin and atenolol on circulating endothelin-1 and von Willebrand factor in hypertensive middle-aged men" J Cardiovasc Pharmacol. (1999) 10.1097/00005344-199910000-00016

[42]

Dong "Efficacy of carvedilol and metoprolol for treatment of primary hypertension and their effects on vascular endothelial function" Zhejiang Med J. (2012) 10.3969/j.issn.1006-2785.2012.11.016

[43]

Makris "Fibrinolytic/hemostatic variables in arterial hypertension: response to treatment with irbesartan or atenolol" Am J Hypertens. (2000) 10.1016/s0895-7061(00)00262-4

[44]

Herrmann "A long-term study of the effects of celiprolol on blood pressure and lipid-associated risk factors" Am Heart J. (1988) 10.1016/0002-8703(88)90133-0

[45]

Fallois "Nebivolol, a beta blocker of the 3rd generation: modern therapy of arterial hypertension. Results of a multicenter observation study" Praxis. (2001)

[46]

Lacourcière "Comparative effects of a new cardioselective beta-blocker nebivolol and nifedipine sustained-release on 24-hour ambulatory blood pressure and plasma lipoproteins" J Clin Pharmacol. (1992) 10.1002/j.1552-4604.1992.tb05778.x

[47]

Liu "Nifedipine inhibits the activation of inflammatory and immune reactions in viral myocarditis" Life Sci. (2009) 10.1016/j.lfs.2009.05.018

[48]

Derosa "Perindopril and barnidipine alone or combined with simvastatin on hepatic steatosis and inflammatory parameters in hypertensive patients" Eur J Pharmacol. (2015) 10.1016/j.ejphar.2015.09.030

[49]

Jiang "Clinical efficacy of atorvastatin calcium combined with nifedipine sustained-release tablets in the treatment of hypertension and its effect on TNF-α, CRP, IL-4 and IL-10" Chin J Integ Med Cardio/Cerebrovasc Dis. (2019) 10.12102/j.issn.1672-1349.2019.04.020

[50]

Martinez "Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension" J Cardiovasc Pharmacol. (2006) 10.1097/01.fjc.0000196241.96759.71

Showing 50 of 81 references

Metrics

4

Citations

81

References

Details

Published: Jan 09, 2023
Vol/Issue: 10
License: View

Authors

Z

Zhe Liu

Guangdong Provincial Institution of Public Health, Guangzhou, China; Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, China

Baylor College of Medicine

C

Chunyu Xu

Authors' Affiliations: Departments of 1Melanoma Medical Oncology and 2Immunology, Center for Cancer Immunology Research; 3Department of Systems Biology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas; Divisions of 4Surgical Oncology and 5Medical Oncology, Massachusetts General Hospital, Boston, Massachusetts

Chinese Academy of Sciences

H

Haijing Zhang

The Education University of Hong Kong

Cite This Article

Zhe Liu, Qin Wang, Na Li, et al. (2023). Cardiovascular benefits of air purifier in patients with stable coronary artery disease: A randomized single-blind crossover study. Frontiers in Public Health, 10. https://doi.org/10.3389/fpubh.2022.1082327

Cardiovascular benefits of air purifier in patients with stable coronary artery disease: A randomized single-blind crossover study

You May Also Like